The “cocktail of antibodies” AZD7442, developed by AstraZeneca for the prevention of COVID-19 disease, was ineffective. The Swedish-British pharmaceutical company reported that the drug was only 33% effective in its third phase of trials.
More than 1.1 thousand unvaccinated adults in the United States and Great Britain with confirmed contact with a person infected with the SARS-CoV-2 virus, no earlier than eight days before taking the drug, participated in the study. However, all participants had negative PCR tests at the time they entered the clinical trial. Overall, AZD7442 reduced the risk of developing symptomatic COVID-19 by 33% compared to placebo.
Earlier, the company agreed to supply the American authorities with up to 600 thousand doses of AZD7442 in case of its successful tests. Now the parties intend to discuss further prospects for cooperation.